We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Autoimmune Antibody Identified as Biomarker for Tachycardia Syndrome

By LabMedica International staff writers
Posted on 16 Sep 2019
Results published in a recent paper suggested that postural orthostatic tachycardia syndrome (POTS) was probably an autoimmune disorder and may boost the development of a simple blood test to diagnose the condition.

Postural orthostatic tachycardia syndrome (POTS) is a condition in which a change in position from lying to standing causes an abnormally large increase in heart rate. More...
This occurs with symptoms that may include lightheadedness, trouble thinking, blurred vision, or weakness. Other commonly associated conditions include irritable bowel syndrome, insomnia, chronic headaches, Ehlers–Danlos syndrome, chronic fatigue syndrome, and fibromyalgia.

The causes of POTS are varied. Often, it begins after a viral infection, surgery or pregnancy. Risk factors include a family history of the condition. Diagnosis in adults is based on an increase in heart rate of more than 30 beats per minute within ten minutes of standing up which is accompanied by symptoms.

Investigators at the University of Toledo (OH, USA) collected detailed clinical symptoms from 55 patients (including 52 females with an average age of 30 years) diagnosed with POTS. They also evaluated serum levels of autoantibodies against four subtypes of G‐protein coupled adrenergic receptors and five subtypes of G‐protein coupled muscarinic acetylcholine receptors by ELISA.

Results revealed a significant number of patients with elevated levels of autoantibodies against the adrenergic alpha 1 receptor (89%) and against the muscarinic acetylcholine M4 receptor (53%). Four patients had elevations of G‐protein coupled autoantibodies against all nine receptor subtypes measured in the study. Five POTS patients had no elevation of any autoantibody; similarly, controls were also negative for autoantibody elevations.

The results indicated that autoantibodies against adrenergic A1 subtype receptor would be present in about 90% of patients with POTS, which suggested that this receptor could serve as a biomarker for diagnosis of the disorder.

"The trouble with diagnosing POTS is that it is currently principally a clinical diagnosis. It is based on history, the absence of other illness as well as the finding of increase in heart rate when standing. There is no blood test right now to aid in the diagnosis. It can be an incredibly frustrating process for patients," said senior author Dr. Blair Grubb, professor of medicine and pediatrics at the University of Toledo. "People have suspected an autoimmune connection for years, and other small-scale studies have suggested it. We did a much larger cross-section of patients than has ever been done before, and found that almost all of them tested positive for autoimmune antibodies. That is a significant finding."

The POTS autoimmune antibody study was published in the September 9, 2019, online edition of the Journal of the American Heart Association.

Related Links:
University of Toledo


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.